Moderna Sees Unusually Large Options Volume (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) saw some unusual options trading on Tuesday. Stock traders bought 179,268 call options on the stock. This is an increase of 83% compared to the typical daily volume of 97,935 call options.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a report on Friday, November 8th. HSBC upgraded Moderna from a "hold" rating to a "buy" rating and set a $58.00 target price for the company in a research note on Monday, November 18th. JPMorgan Chase & Co. cut their price target on Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a research note on Tuesday, November 26th. Leerink Partners lowered their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Finally, Morgan Stanley dropped their price objective on Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a report on Wednesday, January 15th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Moderna currently has a consensus rating of "Hold" and a consensus target price of $60.63.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,664 shares of company stock valued at $115,210 over the last three months. 15.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Moderna

Large investors have recently bought and sold shares of the business. Blue Trust Inc. raised its position in shares of Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company's stock worth $49,000 after purchasing an additional 574 shares during the period. Wilmington Savings Fund Society FSB grew its stake in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares during the last quarter. Venturi Wealth Management LLC increased its position in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares during the period. Compass Planning Associates Inc acquired a new stake in Moderna in the fourth quarter worth $37,000. Finally, Larson Financial Group LLC lifted its stake in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after buying an additional 317 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Shares of Moderna stock traded up $1.80 during trading hours on Friday, reaching $35.53. The company's stock had a trading volume of 21,324,853 shares, compared to its average volume of 13,159,273. Moderna has a one year low of $29.25 and a one year high of $170.47. The company's 50 day simple moving average is $38.17 and its 200 day simple moving average is $53.20. The stock has a market cap of $13.67 billion, a P/E ratio of -3.83 and a beta of 1.59.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.